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Abstract Pharmacological prophylaxis for preventing
venous thromboembolism (VTE) is a worldwide estab-
lished procedure in hip and knee replacement surgery, as
well as in the treatment of femoral neck fractures, but few
data exist in other fields of orthopaedics and traumatology.
Thus, no guidelines or recommendations are available in
the literature except for a limited number of weak state-
ments about knee arthroscopy and lower limb fractures. In
any case, none of them are a multidisciplinary effort as the
one here presented. The Italian Society for Studies on
Haemostasis and Thrombosis (SISET), the Italian Society
of Orthopaedics and Traumatology (SIOT), the Association
of Orthopaedic Traumatology of Italian Hospitals (OTO-
DI), together with the Italian Society of Anesthesia,
Analgesia, Resuscitation and Intensive Care (SIAARTI)
and the Italian Society of General Medicine (SIMG) have
set down easy and quick suggestions for VTE prophylaxis
in a number of surgical conditions for which only scarce
evidence is available. This inter-society consensus state-
ment aims at simplifying the approach to VTE prophylaxis
in the single patient with the goal to improve its clinical
application.
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Introduction
Venous thromboembolism (VTE) has a significant clinical
and social impact due to its high incidence and severe
possible sequelae. Pulmonary embolism (PE), with or
without concomitant measurable deep vein thrombosis
(DVT), is the direct cause of roughly 10 % of hospital
deaths [1]. Although anticoagulant prophylaxis for VTE
has been routine practice for a long time, the literature on
the subject is by no means comprehensive and unequivocal,
especially in orthopaedic and trauma surgery. This
prompted SISET (the Italian Association for the Study of
Haemostasis and Thrombosis), SIOT (the Italian Associa-
tion of Orthopaedics and Traumatology), OTODI (the
Italian Association of Hospital Orthopaedics and Trauma-
tology) and SIAARTI (the Italian Society of Anaesthesia,
Analgesia, Resuscitation and Intensive Care) to set up a
working group in 2009 to define an inter-association con-
sensus statement providing practical recommendations for
the daily management of VTE prophylaxis in hip and knee
replacement surgeries and the treatment of femoral neck
fractures.
The publication and success of this consensus docu-
ment [2] led to the demand for a similar document
regarding VTE prophylaxis in the remaining major
orthopaedic surgeries, the so-called minor orthopaedic
surgeries and orthopaedic trauma. A scarce and low level
of evidence is available in literature for those orthopae-
dic daily life topics. Furthermore, they are only partially
and superficially approached in guidelines. This new
consensus statement was, therefore, drawn up to provide
a comprehensive series of practical and easily applicable
advices to further widespread good clinical practice in
the field.
As a substantial number of patients, who are the object
of this consensus, are not hospitalized, representatives from
SIMG (the Italian Society of General Medicine) were
invited to join the working group, due to the key role of
general practitioners in their continuity of care.
Methods
Although best-clinical-practice guidelines are a funda-
mental tool for health care providers, there are many
important fields in which the scarcity of the literature does
not allow strong evidence-based recommendations to be
made. This is the case for VTE prophylaxis in a significant
part of orthopaedics and traumatology. Indeed, although
the existing guidelines (ACCP [1] and NICE [3]) have been
recently revised and updated by authoritative working
groups using rigorous scientific method, they are complex
documents that are not particularly clinician-friendly.
Furthermore, the chapters on musculoskeletal pathologies
and orthopaedic surgery cover only a small number of the
wide range of pathologies and treatments that clinicians
have to manage on a daily basis. This is an accurate
reflection of the international literature as a whole, which
features an abundance of information on certain topics and
virtually none on others [4]. The solution to this problem
adopted by NICE and ACCP was, in brief, to supply the
guidelines that can be backed up by scientific evidence, and
to ignore the rest. Though this approach is not questionable
from a formal perspective, it is, however, lacking from a
clinician’s point of view. Hence, drawing on the pragmatic
spirit that inspired the first publication of the consensus
statement on antithrombotic prophylaxis in hip and knee
replacement surgeries and femoral head fractures [2], the
intersociety working group decided to fill the void and
produce a document more useful for clinical practitioners,
as the previous one.
A work plan was set up to respond to the practical needs
of the clinicians, allocating the orthopaedic and traumatic
pathologies to simple but workable categories. The litera-
ture regarding each of these categories was analysed from a
practical point of view, using advanced but non-coercive
methods, in order to provide as large a pool of relevant
information as possible. The sources thereby obtained were
then processed and summarized prior to screening by the
working group in a series of plenary sessions, until a
consensus was obtained.
In certain cases the process was greatly facilitated by the
above mentioned NICE [3] and ACCP [1] guidelines,
whereas in others it was a more arduous task. Nonetheless,
consensus was reached in each case, following open debate
giving the appropriate weight to literature reports, clinical
experience and contextual clues. As the working group is
fully aware of the limitations of such an approach, the
authors decided to avoid making true ‘recommendations’,
instead limiting themselves to inviting the clinician to
consider prophylaxis or not in each particular case. Despite
the impossibility of providing firm, evidence-based
guidelines, the group was convinced of the necessity of a
reference text on these issues, and therefore, set out to
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include the current state-of-the-art in a document that is in
effect a compromise between methodological rigour and
clinical pragmatism.
Thrombotic risk
The risk of VTE associated with surgery or orthopaedic
trauma is conditioned by the interaction of two types of
factors: (a) individual risk factors, linked to the conditions
and characteristics of the patients themselves, and
(b) treatment-related factors, arising from the specific
features and consequences of the surgical or non-surgical
procedure employed.
Patient-related risk factors [5–11]
There are numerous patient-related risk factors (Table 1),
which act through various pathogenic mechanisms that
contribute to the generation of venous stasis and/or
increase a state of hypercoagulability. The risk of venous
stasis increases with age (due to decreased motor activity),
obesity, immobilization (transitory or permanent) or con-
finement to bed for several days, trauma, application of
plaster casts, and varicose veins. Numerous patient-related
risk factors, whether congenital or acquired, transient or
permanent, promote hypercoagulability, and consequently
increase the risk of thrombosis.
An established significant risk factor is a past history of
VTE, whether idiopathic or stimulated by a specific trigger.
Familial history of VTE should also be considered as a risk
factor. Aging is also a favourable condition for VTE, as it
is associated with increased blood coagulability. Likewise,
the presence of one or more thrombophilic conditions
(congenital or acquired, see Table 2), today well docu-
mented and clinically significant, involves an increased
risk. While this is not a call for screening general popu-
lation or pre-operative patients for thrombophilic condi-
tion, clinicians should take particularly care assessing
anamnestic and known risk factors.
Several physiological states, such as pregnancy and
puerperium or iatrogenic conditions, like oral contracep-
tives or hormone replacement therapy (HRT), are well
known thrombosis risk factors, and may, alone, justify
VTE prophylaxis. If a woman assuming oral contraceptives
or HRT is scheduled for surgery, it would be wise to sus-
pend the therapy at least 1 month prior to the operation. In
case of an urgent need of surgery, she should immediately
suspend those medications and be considered at a higher
risk for thrombosis.
Finally, an extremely significant risk factor for throm-
bosis is the presence of diseases such as neoplasms, heart
failure, respiratory failure, inflammatory bowel disease,
nephrotic syndrome, sepsis, or a recent history of myo-
cardial infarction or stroke. In all these cases, therefore,
prophylaxis should be considered.
Treatment-related risk factors [12–15]
In orthopaedic surgery, the risk of thrombosis, and there-
fore, the need for prophylaxis, can generally be considered
as proportional to the duration and invasiveness (trauma,
demolition) of the surgical procedure. Other surgery-rela-
ted factors that may influence the likelihood of
Table 1 Individual risk factors that could suggest a pharmacological
VTE prophylaxis
Risk factor
Individual or family history of VTE (first degree relatives) XX
Known congenital or acquired thrombophilia (Table 2) XX
Active cancer or cancer treatment XX
Obesity (BMI [30) XX
Bed confinement ([3 days) XX
Impediment to normal ambulation (weight bearing\10–20 kg,
lower extremity immobilisation)
X
Age ([60–70 years) X
Oestrogen contraceptive therapy or hormone replacement
surgery (ongoing or within 1 month after suspension)
X
Pregnancy or puerperium (6 weeks after delivery) X
Recent acute myocardial infarction (AMI) or stroke X
Chronic heart failure X
Chronic respiratory failure X
Inflammatory bowel disease X
Sepsis or severe infections X
Large varicose veins X
Nephrotic syndrome X
XX factors associated with a high risk, X factors associated with a
moderate risk







R506Q (Leiden) factor V mutation
G20210A prothrombin mutation
Acquired
Lupus anticoagulant syndrome (LAC)
Presence of antiphospholipid antibodies
Anticardiolipin and/or
Anti-beta2glycoprotein I
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thrombogenesis are: the position of the patient on the
operating table (particularly if prone), any forced twisting
or traction of a limb that could damage the blood vessels,
and the use of additional medical devices (in particular, the
tourniquet). One significant thrombotic risk factor in both
surgical and non-surgical interventions (lower limb plaster
casts, brace, splints or appliance) is the length of time
before the patient returns to normal ambulation. In fact,
compression on the plantar venous plexus brought about by
normal ambulation, and the concomitant activation of the
calf muscle pump, are key factors to ensuring the cen-
tripetal venous return. Ambulatory patients with fully
functional feet and ankle movements are, therefore, far less
likely to develop venous stasis. Hence, as venous stasis can
cause thrombogenesis (particularly in the calf), the need for
antithrombotic prophylaxis should be evaluated in cases of
impediment to normal ambulation and calf muscle function
(ankle/calf splinting or casting and/or non-weight bearing,
NWB). Although the precise contribution of plantar venous
plexus compression and calf muscle pump function to the
circulation has not been evaluated, and firm evidence is,
therefore, lacking, a load of 10–20 kg should be considered
the minimum for its activation.
Haemorrhagic risk
Pharmacological VTE prophylaxis is based on the use of
anticoagulants, whose use is limited in patients at high risk
of haemorrhage, where inhibition of the physiological
mechanisms responsible for the regulation of thrombus
formation can trigger or worse bleeding. Unlike the more
precise and individual stratification of thrombotic risk,
even in the latest guidelines (for example, ACCP [1] and
NICE [3]) the definition of haemorrhagic risk is limited to
mere suggestions, ‘empirical’ recommendations, frequently
not supported by clinical trials. Contraindications to phar-
macological prophylaxis for VTE are reported as absolute
or relative, but even in the definition of the absolute rec-
ommendations there is some discrepancy between different
sources. For example, according to NICE [3] guidelines, a
platelet count of \20,000/lL is an absolute contraindica-
tion, whereas in other statements the thrombocytopenia
cut-off point is higher, at \50,000/lL. Likewise, there is
considerable disparity in the information sheets provided
with drugs used in VTE prophylaxis (LMWH and fonda-
parinux, for instance), particularly between the respective
manufacturers’ warnings and absolute contraindications.
These information sheets also tend to feature vague terms
such as ‘clinically relevant bleeding’ or ‘lesions at risk of
bleeding’, and therefore the decision of whether or not to
begin prophylaxis needs to be made on a patient-by-patient
basis, based on the clinician’s evaluation of the haemor-
rhagic risk versus the thrombotic risk.
Absolute contraindications [1, 3, 16, 17]
• Active bleeding
• Untreated congenital coagulopathies (haemophilia and
severe von Willebrand disease)
High haemorrhagic risk factors (decisions
on an individual case basis) [1, 3, 16, 17]
• Individual or family history of major haemorrhage
• Acquired coagulopathies (e.g., hepatic insufficiency
with abnormal coagulation test results and/or platelet
count)
• PT ratio or PT-INR [1.5
• APTT [1.25 (except in cases with antiphospholipid
antibodies and no history of haemorrhage)
• Thrombocytopenia (\50,000/lL)
• Severe renal failure (creatinine clearance\30 mL/min)
• Cerebral metastases or cerebral angioma at risk of
bleeding (confirmed by CT angiography or MRI)
• Recent haemorrhagic stroke or ischemic stroke (24 h)
• Gastric and/or genitourinary or ocular haemorrhage
within the previous 2 weeks
• Medicines acting on haemostasis (e.g., anti-platelet,
anti-inflammatory drugs)
• III degree arterial hypertension (230/120 mmHg)
• Acute infectious endocarditis (except that due to
mechanical prostheses)
Wherever possible and indicated, the haemostatic defect
should be corrected via transfusion or pharmacological
means; severely hypertensive patients should receive the
appropriate treatment, and the risk/benefit ratio of sus-
pending anti-platelet or anti-inflammatory drugs should be
evaluated. In cases of high haemorrhagic risk, mechanical
and/or pharmacological prophylaxis (assessing the need to
reduce dosage and/or start the administration only post-
surgery) can be considered. When the high risk is transient,
antithrombotic prophylaxis should be started as soon as the
haemorrhagic risk is under control, and continued until the
risk of thrombosis persists.
Blood tests essential for assessing the degree
of haemorrhagic risk
• Complete blood count to obtain:
(a) Prothrombin time (PT)
(b) Activated partial thromboplastin time (APTT)
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• In all patients needing pharmacological antithrombotic
prophylaxis, it is advisable to evaluate both the
thrombotic risk and the haemorrhagic risk, identifying
patients at high risk and those who will need careful
evaluation.
• In patients who cannot be prescribed pharmacological
prophylaxis, it is advisable to use mechanical devices
such as graduated compression stockings (GCS) or, in
cases of high thrombotic risk, intermittent pneumatic
compression (IPC) or plantar venous pump (PVP).
• When the contraindication is temporary, it is advisable
to start pharmacological antithrombotic prophylaxis as
soon as the haemorrhagic risk is under control, for as
long as the thrombotic risk persists.
VTE prophylaxis
In minor orthopaedic and trauma cases, VTE prophylaxis
can be pharmacological (LMWH), mechanical (either
active, i.e., IPC and PVP, or passive, i.e., GCS), or com-
bined (pharmacological and mechanical) [1–3].
Pharmacological prophylaxis [1–3]
Nowadays, pharmacological prophylaxis is essentially
based on LMWH (bemiparin, dalteparin, enoxaparin, na-
droparin, parnaparin or reviparin), although unfractionated
heparin can be used in certain cases (1). As regards LMWH
administration, although scientific studies identifying the
optimal dose have not been published yet, it is advisable to
give high doses (Table 3). Lower doses should, however,
be considered in ‘‘fragile’’ patients (e.g., low body weight,
renal insufficiency) (see information sheets provided with
pharmaceuticals).
Mechanical prophylaxis [1–3]
Mechanical prophylaxis is based on the use of elastic
compression stockings (passive mechanical prophylaxis)
and intermittent pneumatic pumps (active mechanical
prophylaxis) [1, 3].
Passive mechanical prophylaxis (thigh–foot or knee–
foot stockings) increases the efficacy of pharmacological
prophylaxis, and should be employed (bilaterally if possi-
ble) until good mobility and autonomous ambulation are
recovered. Care must also be taken to ensure stockings are
applied correctly (i.e., not too tight/loose) by the nursing
staff and/or the patients themselves. It should not, however,
be prescribed if the patient has peripheral artery disease or
diabetic neuropathy [1, 18].
Intermittent pneumatic compression pumps (sural or
plantar) are highly efficacious and increase the action of
anticoagulants, although their management has less com-
pliance from nurses and patients [1].
Elective indications for mechanical prophylaxis are high
risk of thrombosis accompanied by contraindications to
pharmacological prophylaxis. In minor orthopaedic sur-
gery, passive mechanical prophylaxis is often the only
advisable prophylaxis in low-risk patients [1, 3].
Timing of VTE prophylaxis
Arthroscopic surgery
Unlike hip or knee prosthetic surgery, where some studies
and meta-analyses have been reported (with no significant
differences between pre- and post-operative administration
of pharmacological prophylaxis), there is no literature
concerning the differences in terms of efficacy and safety
of pre-surgical and post-surgical LMWH administration in




Brand name Dose and timing




38 IU/kg 12 h before the operation and
12 h afterward, 38 IU/kg every 24 h
over the next 3 days after surgery,
then increasing the dose to 57 IU/kg/
day
Dalteparin Fragmin 5,000 IU 8–12 h before the operation,
then 5,000 IU/day
Alternatively, 2,500 IU 1–2 h before
surgerya and 2,500 IU 8–12 after, then
5000 IU/day
Bemiparin Ivor 3,500 IU 6 h after surgery, then
3,500 IU/day
Alternatively, 3,500 IU 2 h before
surgerya, then 3,500 IU/day
Parnaparin Fluxum 4,250 IU anti-Xa 12 h before the
operation, then 4,250 IU anti-Xa/day
Reviparin Clivarina 4,200 IU anti-Xa 12 h before the
operation, then 4,200 IU anti-Xa/day
a Despite the manufacturer’s instructions, pre-operative administra-
tion is not advised for these specific patients by this working group
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arthroscopic surgery. Nonetheless, the working group
reached the consensus that post-operative start would be
wiser, even though in Italy the manufacturers recommend
pre-operative administration (with the exception of
bemiparin).
Non-arthroscopic orthopaedic surgery
Post-operative start of prophylaxis is also advisable in this
case.
Emergency trauma surgery
For femoral neck fractures (see also the 2010 Intersociety
consensus statement [2]), timing for an appropriate pro-
phylaxis is strictly dependent on scheduled surgery:
• If surgery is performed immediately (within 24 h of the
trauma), it is possible to start LMWH (12 h before or
12 h after surgery).
• If surgery is postponed, LMWH should be given early
on, as soon as haemorrhagic contraindications (e.g.,
multiple traumas, severe head trauma) have been ruled
out, then suspended 12 h prior to surgery and recom-
menced 12 h afterwards.
• Fondaparinux or new oral anticoagulants should not be
used.
Non-surgical traumatology
In this case, antithrombotic prophylaxis (when indicated)
should be started upon non-weight bearing and/or appli-
cation of the cast or splint, etc.
Duration of pharmacological prophylaxis
When indicated, the pharmacological prophylaxis should
be administered for a minimum of 7 days. The duration of
the prophylaxis should take into account the persistence of
thromboembolic risk factors and the recovery of mobility
and weight bearing (at least 10–20 kg).
Special considerations in paediatric patients
A hotly debated issue in the working group meetings
was pharmacological prophylaxis in paediatric patients
(\18 years), particularly as little evidence is available in
literature. In general, paediatric patients have a low risk
of thrombosis, but this can be increased by other risk
factors. In order to provide general indications for clin-
ical application, the group analysed the data from the
New York Stony Brook University Hospital trauma
register [19]. No VTE was observed in any of over 1,000
trauma patients under 13 years of age who were not
given prophylaxis. In over 1,000 13–17-year-old patients
who were given prophylaxis, following the instructions
of the individual surgeons, two episodes of VTE were
recorded. More recent data, obtained in a traumatology
setting [20, 21], confirm the low risk of VTE in paedi-
atric patients.
Systematic pharmacological prophylaxis therefore finds
no justification, but patients at greater risk need to be
identified. No information on paediatric orthopaedic sur-
gery was found in the literature, but general guidelines on
hospitalized patients have recently been published by the
Tuscany Regional Council [22].
The consensus on paediatric patients scheduled for
major surgery was as follows:
• Pharmacological prophylaxis is not advisable in pre-
pubertal patients, except in cases deemed to be at
particular risk of thromboembolism.
• In pubertal and post-pubertal patients it is advisable to
identify any risk factor and decide on individual case
basis whether prophylaxis should be only mechanical
or also pharmacological.
Among factors influencing such decision, particular
attention should be paid to the presence of central vein
catheterization and/or a previous history of VTE. It is also
crucial taking into consideration obesity, family history of
VTE at a young age (\50 years), parenteral nutrition,
prolonged sedation, neuromuscular block, acute infection,
the presence of neoplastic disease, major trauma and
chronic illness.
Classification of orthopaedic and trauma surgeries
Surgical procedures in orthopaedics and traumatology fall
into four general categories: major orthopaedic surgery,
minor orthopaedic surgery, major trauma surgery, and
minor trauma surgery. Whether surgery is classified as
major or minor will depend on a series of parameters,
namely:
• The nature of the pathology
• Complexity and invasiveness of the treatment
• Technology required
• Comorbidity
Prophylaxis in orthopaedic and trauma surgery
This section is dedicated to prophylactic approaches in
various orthopaedic and trauma surgery procedures.




VTE is a very rare but serious complication of spinal
surgery. Analysis of the limited literature available
reveals that the incidence of VTE appears to vary
according to the presence of several factors as the
invasiveness of surgery, the period of immobilization, the
neurological damage and patient age [23–25]. The short
period of time the patient is bed-bound following surgery
is presumably one of the primary causes of low inci-
dence of VTE. Posterior approach, the most common
used, is associated with a very low incidence of VTE
and any prophylaxis should, therefore, be chosen for its
limited risk of complications. Indeed, pharmacological
prophylaxis, which entails an increased risk of bleeding,
could result in catastrophic compression of nervous
system.
Type of prophylaxis Mechanical prophylaxis (GCS, IPC)
should be prescribed in cases of delayed recovery of
ambulation, as its recognized beneficial effects are
accompanied by an absence of correlated haemorrhagic
complications. Pharmacological prophylaxis (LMWH),
however, should be considered in cases of:
• Prolonged and/or complex surgery (e.g., combined
anterior and posterior approaches)
• Patients with relevant VTE risk factors (see ‘‘Throm-
botic risk’’).
Timing and duration of prophylaxis In the absence of
evidence, the post-operative use of GCS is advisable until
ambulation is recovered. Where pharmacological prophy-
laxis is deemed necessary, LMWH should be given after
surgery and continued until normal ambulation is resumed.
Elective surgery of the pelvis and proximal femur
(excluding prosthetic surgery)
Elective surgery of the pelvis and proximal femur (repre-
sented essentially by osteotomies and oncological surgery)
has potentially a high risk of thromboembolism, and
should, therefore, be considered as hip replacement
surgery. Thus, albeit with no supporting evidence, phar-
macological prophylaxis would be a wise precaution [1,
26, 27].
Type of prophylaxis Pharmacological prophylaxis with
LMWH or fondaparinux is advisable. Post-operative use of
GCS, as an additional aid, might also be considered until
ambulation is recovered.
Timing and duration of prophylaxis It is advisable to start
pharmacological prophylaxis in the post-operative period,
and to continue until ambulation is resumed.
Elective knee surgery (excluding prosthetic surgery)
The need for VTE prophylaxis in patients undergoing
elective knee surgery remains controversial, and it is nec-
essary to distinguish between different types of procedure
(major and minor) and the duration of the immobilization
period [28–30].
Type of prophylaxis Pharmacological prophylaxis with
LMWH is advisable in major surgery. Pharmacological
prophylaxis with LMWH is advisable in minor surgery
only in the presence of additional risk factors linked to the
procedure, such as, for example, the use of a tourniquet or
non-weight bearing. Post-operative use of GCS, as an
additional aid, may also be considered until ambulation is
recovered.
Timing and duration of prophylaxis Administration of
pharmacological prophylaxis in the post-operative period is
advised. The duration of prophylaxis should coincide with
the period of immobilization of the limb or non-weight
bearing. A minimum prophylaxis duration of 7 days is
suggested.
Foot or ankle surgery
VTE risk in foot surgery has barely been studied. Never-
theless, the little available data from retrospective studies
shows that the incidence of DVT ranges from 0.16 to 4 %,
and that of PE from 0 to 0.15 % [31–35].
Type of prophylaxis VTE prophylaxis is not advisable for
patients with no risk factors. In those featuring general or
surgery-related risk factors, such as, for instance, the use of
a tourniquet, non-weight bearing, or ankle immobilization,
pharmacological prophylaxis with LMWH should be
considered.
Timing and duration of prophylaxis Pharmacological
prophylaxis in the post-operative period is advised. Pro-
phylaxis duration should coincide with the period of
immobilization of the limb or until weight bearing is
resumed. A minimum prophylaxis of 7 days is advised
when indicated.
Upper limb surgery
VTE is considered a rare complication in upper limb sur-
gery and non-prosthetic surgery of the shoulder. In
J Orthopaed Traumatol (2013) 14:1–13 7
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prosthetic surgery of the shoulder, a retrospective study
reported a DVT incidence of 0.5 % [36, 37].
Type of prophylaxis Pharmacological prophylaxis with
LMWH is advised in prosthetic surgery of the shoulder.
Pharmacological prophylaxis with LMWH should be consid-
ered in non-prosthetic surgery patients presenting risk factors.
Timing and duration of prophylaxis It would be advisable
to start pharmacological prophylaxis in the post-operative
period. A minimum prophylaxis duration of 7 days is
advised, and should accordingly be prolonged in patients
confined to bed for an extended period.
Hip arthroscopy
VTE risk in hip arthroscopy has barely been evaluated, but
retrospective studies appear to indicate an incidence
ranging from 0 to 3.7 % [38–40] in the absence on
prophylaxis.
Type of prophylaxis VTE prophylaxis is not advisable for
patients presenting no risk factors. Pharmacological pro-
phylaxis with LMWH should be considered in patients
featuring general or procedure-related risk factors, such as
a prolonged surgery or non-weight bearing.
Timing and duration of prophylaxis Administration of
pharmacological prophylaxis in the post-operative period is
advisable. Prophylaxis should be continued until the patient
is able to bear weight, and, in any case, for at least 7 days.
GCS may be advisable, as an additional aid, to be worn
until the patient resumes ambulation.
Knee arthroscopy
This is the most studied type of arthroscopy as regards
VTE risk [18, 27, 38, 41]. We distinguish between two
types of knee arthroscopy, namely, major (i.e., ligament
reconstruction) and minor (i.e., selective meniscectomy). A
specific risk factor associated with knee arthroscopy is
tourniquet use, especially if this is kept in place for longer
than 60 min. Several studies have demonstrated the effi-
cacy of LMWH in reducing the risk of VTE in this type of
surgery without increasing the risk of haemorrhage.
Type of prophylaxis Pharmacological prophylaxis with
LMWH is always advisable in major surgery or in minor
procedures if in presence of general or surgery-related risk
factors, i.e., prolonged tourniquet application or non-
weight bearing. Post-operative prescription of adjunctive
GCS may also be considered until the patient resumes
ambulation.
Timing and duration of prophylaxis Pharmacological
prophylaxis, when indicated, should be started postopera-
tively and its duration should coincide with limb immobi-
lization or non-weight bearing. A minimum prophylaxis
duration of 7 days is advised.
Ankle arthroscopy
Ankle arthroscopy surgery has been little analysed in terms
of VTE risk [38]. Nevertheless, the incidence of VTE after
ankle arthroscopy, extrapolated from a review of 15 studies
(a total of 1,367 patients), appears to be 0 %.
Type of prophylaxis VTE prophylaxis is, therefore, not
advised in patients without risk factors. In patients with
general or surgery-related risk factors, e.g., tourniquet
application, ankle immobilization and non-weight bearing,
pharmacological prophylaxis with LMWH should be
considered.
Timing and duration of prophylaxis Pharmacological
prophylaxis is advised, when indicated, starting in the post-
operative period. It should be administered for at least
7 days, and continued until mobilization and weight
bearing.
Shoulder arthroscopy
Thromboembolic complications are very rare after shoul-
der arthroscopy, with a reported incidence of VTE of less
than 0.01 % [36, 42].
Type of prophylaxis VTE prophylaxis is not advisable in
all patients, although those who feature risk factors may
benefit from administration of LMWH.
Timing and duration of prophylaxis Pharmacological
prophylaxis, when indicated, should be started in the post-
operative period, to be continued for at least 7 days.
Elbow or wrist arthroscopy
Neither elbow nor wrist arthroscopy have been studied as
regards VTE risk and prophylaxis.
Type of prophylaxis VTE prophylaxis is not advised.
Trauma surgery
Amyelic vertebral fractures
There are two distinct types of treatment, surgical and
conservative.
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Surgical treatment See the section on elective spinal
surgery.
Conservative treatment This is performed by means of
casts or brace designed to immobilize the spine for
60–90 days. The patient may or may not be confined to bed
for the first month.
Type of prophylaxis Mechanical prophylaxis via GCS is
advised.
Pharmacological prophylaxis may be advisable in cases
of:
– Bed confinement
– Low mobility in patients featuring risk factors.
Timing and duration of prophylaxis In cases of pharma-
cological prophylaxis, LMWH is advised, normally for
30 days, or less, if patient restores ambulation.
Upper limb fracture
VTE is considered a rare complication of upper limb or
shoulder fracture.
Surgical treatment See the section on elective surgery of
the shoulder and upper limb.
Conservative treatment The limb is immobilized by
means of casts or specific braces.
Type of prophylaxis Pharmacological prophylaxis
(LMWH) is advisable only in cases of:
• Bed confinement
• Poorly mobile patients with risk factors
• Crushing injuries
Timing and duration of prophylaxis LMWH is suggested,
when pharmacological prophylaxis is required, normally
for 30 days or until the patient restores mobility.
Pelvic or acetabulum fracture
Pelvic and acetabulum trauma presents a high risk of
thromboembolism in both unstable fractures requiring
surgery and stable fractures, due to the need for bed con-
finement [26, 27, 43–45]. In cases of multiple fractures, the
high risk of VTE is not usually associated with an increase
in haemorrhagic risk. In cases of multiple traumas, how-
ever, haemorrhagic risk needs to be considered greater than
VTE risk, and pharmacological prophylaxis should be
delayed until patient’s haemostatic conditions have been
stabilized.
Surgical treatment See the section on elective pelvic
surgery.
Conservative treatment Stable lesions that require no
surgical treatment usually are treated with non-weight
bearing periods of 3–5 weeks, and will, therefore, feature a
high risk of VTE.
Type of prophylaxis Pharmacological prophylaxis with
LMWH is advised, and GCS should be considered as an
additional aid until ambulation is resumed.
Timing and duration of prophylaxis It is advisable to
continue prophylaxis until ambulation is restored.
Lower limb fracture and traumatic lesions requiring
immobilization
The reported incidence of VTE in these cases is somewhat
variable (4.3–40 %). The incidence of total and proximal
DVT in Achilles’ tendon rupture may reach 36 and 7 %,
respectively. In patients with an immobilized lower limb, a
meta-analysis performed on six randomized controlled
trials, revealed a reduction in asymptomatic DVT from
17.1 to 9.6 % with LMWH pharmacological prophylaxis,
without any associated increase in bleeding [28–30].
However, there is considerable controversy in literature
regarding this issue [46–48]. This prompted the working
group to formulate the following advice, which takes into
account the known risk of VTE linked to ankle immobili-
zation, the difficulty in precise risk stratification in an
emergency situation, and the low risk of significant com-
plications associated with pharmacological prophylaxis.
Surgical treatment See the section on elective lower limb
surgery.
Conservative treatment Indications for conservative
treatment with cast or brace are less than in the past but, in
these cases, one or more joints may need to be immobilized.
Type of prophylaxis Pharmacological prophylaxis with
LMWH is advised in lower limb immobilization or com-
plete non-weight bearing.
Timing and duration of prophylaxis Pharmacological
prophylaxis with LMWH is advised until patient is mobi-
lized and ankle mobility and weight bearing are at least
partially restored.
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Anaesthesia issues
The relationships and reciprocal influences on VTE pre-
vention between anaesthesia and orthopaedic and trauma
surgery have been well known for years. This brief sum-
mary aims to outline the key aspects of these complex
interactions.
Pro-coagulant effects of general anaesthesia
The literature, albeit somewhat dated, seems to suggest that
the type of anaesthesia may influence the risk of VTE.
General anaesthesia (GA) may contribute to DVT onset
due to venous stasis through vasodilation and a consequent
increase in venous capacitance and reduction in venous
return, the latter being a further obstacle to the circulatory
effects of positive pressure ventilation. Vasodilation can
also damage the endothelium, thereby exposing the sub-
endothelial layer, which, participating in coagulation cas-
cade activation, promotes thrombus formation [49, 50].
Anticoagulant effects of locoregional anaesthesia
Locoregional anaesthesia (LRA), whether neuraxial or
peripheral, would appear to reduce the incidence of VTE,
at least according to studies performed in vascular and
major orthopaedic surgery on lower limbs [51, 52]. The
mechanisms to explain this effect include rheological
changes in the hyperkinetic blood flow in the lower limbs.
Furthermore, epidural anaesthesia exerts a profibrinolytic
action, which, however, does not seem to be clinically
relevant, except at very high doses [53–56]. The effect on
haemostasis is probably obtained through various mecha-
nisms, including sympathetic afferent nerve blockade, a
reduction in circulating catecholamines, and the pharma-
cological properties of the local anaesthetic systemically
absorbed in small quantities [57–59]. All these combined
effects cohoperate to a lower incidence of thrombosis in
lower limb surgery performed under locoregional
anaesthesia.
Confounding factors
The above mentioned mechanisms of action are difficult to
demonstrate, and, when evaluating the relevant studies, it is
necessary to take into account the variability in surgical
techniques, patient position and fluid management strate-
gies employed, as well as the reduction in cardiac output,
the choice of hypotensive anaesthesia, intra-operative
hypovolaemia, blood loss and hypothermia, all factors that
could play a role in the onset of DVT, irrespective of the
anaesthetic approach used. Moreover, the majority of the
reviewed studies involved patients who were not given the
recommended pharmacological prophylaxis, or, in any
case, were subjected to different prophylaxis regimens
[60].
Upper limb
Upper limb surgery can be performed with patient under
either GA or LRA. LRA techniques involve local anaes-
thetic injection targeting the brachial plexus, at various
levels, and therefore, a temporary blockade of the action
potentials conducted by sensory and motor fibres, mainly
corresponding to the anterior roots between C5 and C7.
Positioning of a perineural catheter allows continuous
perfusion of local anaesthetic to be maintained in the post-
operative period. It also enables more efficacious antalgic
control with respect to systemic analgesia, and possibly a
better control of the stress reaction [61]. No statistically
significant differences have been observed among different
anaesthetic techniques for the incidence of upper limb
DVT, although LRA is known to be associated with less
pain after surgery and early mobilization, especially if
continued in the post-operative period.
Lower limb
Lower limb surgery as well can be performed with the aid
of GA and LRA. In the latter, a distinction needs to be
made between neuraxial LRA and peripheral nerve block.
In terms of early dismissal from the operating theatre, with
the introduction of new rapid-offset anaesthetics, there are
no significant differences between LRA techniques.
Whichever anaesthetic technique is employed, the use of a
tourniquet must be considered as an independent risk fac-
tor, due both to the possibility of vascular endothelial
damage and reperfusion-related phenomena [62].
Epidural analgesia
Its positive effect seems to be linked not only to the pro-
longed efficacy and therefore to the benefits of epidural
analgesia, but overall to a rapid post-operative patient
mobilization, with a reduction of VTE risk [63].
Risk/benefit ratio in the choice of type of anaesthesia
When choosing the anaesthetic technique it is crucial to
accurately weigh up the risk/benefit ratio, taking into
account the risk of thrombosis and/or haemorrhage after a
careful evaluation of the variables involved: patient-rela-
ted, proposed surgical technique, expected blood loss, the
presence of pre-existing pathologies that can themselves
increase the thromboembolic or haemorrhagic risk (cardi-
opathies featuring blood stasis and/or those that require
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prescription of drugs that interfere with coagulation, liver
disease, nephropathies and blood diseases, etc.). Peripheral
blockade should be considered a valid option in these cases
[64]. A more detailed discussion of this issue can be found
in the 2010 intersociety consensus statement [2].
The role of general practitioners (GPs) in VTE
prophylaxis continuation
General practitioners (GPs) are responsible for the care of
patients in the community, and are, therefore, charged with
guaranteeing the continuity of care of patients discharged
from hospital.
The GP has an important role in VTE management.
Minor orthopaedic and trauma patients are quickly dis-
charged by hospitals frequently with a prescription of DVT
prophylaxis.
Maximal VTE risk is in the first 2–3 weeks after trauma
or surgery but the risk lasts for 2–3 months [1, 3]. This is a
period where patients are mainly followed by a GP who is
in first line in recognizing initial DVT-PE signs. Thus, a
specific attention to VTE problems is, today more than
ever, fundamental in the GP’s knowledge.
In fact, the GP is defined as the medical guarantor of
patient health, starting from the basal fundamental actions
necessary to keep as smooth as possible the process of
homecare. The fundamental importance of GPs lies in the
fact that they have a long-term relationship, not only with
individual patients, but also with their close relatives, and
they are, therefore, well informed as regards family, as well
as personal history of illness, in addition to issues such as
reliability, compliance, socioeconomic standing, and living
arrangements. The GP is also seen as the ‘case manager’ in
cases of domiciliary care.
In our specific context, the GP and the attending phy-
sician or surgeon must collaborate to ensure continuity of
care before, during and after hospital treatment. The GP is,
therefore, charged with providing the attending physician
or surgeon with all the information they need to ensure that
the patient can be treated with as few complications as
possible. To this end, information technology tools are
extremely helpful, particularly if the GP highlights relevant
information in a patient’s records, thereby facilitating the
triage procedure. Indeed, it is fundamental that in the case
of scheduled hospitalization the GP is aware of the indi-
vidual risk factors of the patient and records them appro-
priately so they are readily available for consultation upon
admission. In this way, the attending physician or surgeon
can weigh up the specific risks linked to the reasons for
hospitalization alongside those presented by these patient-
related factors. This will give them an accurate idea of the
total risk the patient is likely to be exposed to, and help
them choose the appropriate treatment strategy
accordingly.
Once the patient is discharged from hospital, and
therefore, re-entrusted to the care of the GP, the latter will
need to monitor the patient’s progress and ensure that she/
he adhere to the prescribed treatment, not only in terms of
dosage and duration, but also in terms of behavioural
compliance, as well as being on the look out for any
delayed complications. This is especially true in the present
hospital practice, where many elective surgeries are rapidly
completed, sometimes even on an outpatient basis. Bearing
in mind the key role of GPs, this intersociety consensus
statement was drawn up to give them the best possible
support in deciding whether or not to prescribe treatment in
cases where there is no established risk/benefit ratio, and
therefore, no clear guidelines. Although the same paucity
of evidence also prevented us from making firm recom-
mendations, having reviewed the literature and drawn on
the combined experience of the working group participants,
we are in a position to advise the clinician to consider
whether such treatment may be necessary for the patient.
Conclusions and future directions
This document represents the consensus of Italian experts
in the field, drawn from the scientific state-of-the-art and
available drug labels, as of the summer 2012, and will be
made public by the five participant societies with different
modalities (association journals and/or websites, symposia
at national conferences, etc.).
It is also the authors’ intention to review the consensus
statement on a regular basis, as and when new information
comes to light. The FONDACAST study comparing the
relative efficacies of 2.5 mg fondaparinux and nadroparin
as regards VTE prevention in distal fracture of the lower
limbs and Achilles’ tendon rupture has recently been
concluded, although not yet published. If the preliminary
results are confirmed, fondaparinux may become the drug
of choice in this specific prophylaxis setting in the next
future. Another novelty on the horizon is represented by the
new oral anticoagulants currently being trialled. Although
there are no scheduled trials of these drugs in VTE pre-
vention in situations not involving hip and knee replace-
ment surgery, the expected increased diffusion of new
drugs for stroke prevention in atrial fibrillation will
doubtlessly increase the number of patients under new oral
anticoagulants (e.g., for atrial fibrillation) needing ortho-
paedic surgery.
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